-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1085 Exogenous M-CSF Protects from Lethal a. Fumigatus pulmonary Infection By Tissue-Resident Alveolar Macrophages Early after Hematopoietic Cell Transplantation

Program: Oral and Poster Abstracts
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical Research, Therapies, immunology, Biological Processes
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Dalia Sheta, MSc1,2,3*, Andreas Beilhack, MD4*, Hermann Einsele, MD5, Katrin G Heinze, PhD6*, Zeinab Mokhtari, PhD7,8*, Jorge Amich9*, Ulrich Terpitz10*, Nora Trinks, PhD10*, Marlene Strobel, Msc11* and Yidong Yu, PhD11*

1Department of Internal Medicine II, Division of Oncology and Hematology, Würzburg University Hospital, Würzburg, Germany
2Graduate School of Life Sciences, Julius-Maximilians University, Würzburg, Germany
3Interdisciplinary Center for Clinical Research Laboratory, Würzburg University Hospital, Würzburg, Germany
4Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
5Department of Medicine II, Division of Oncology and Hematology, Würzburg University Hospital, Würzburg, Germany
6Rudolf-Virchow-Center, University of Würzburg, Germany, Würzburg, Germany
7Glaxosmithkline Gmbh & co. kg, Heidelberg, Germany
8glaxosmithkline gmbh & co. kg, Heidelberg, Germany
9Manchester Fungal Infection Group (MFIG), School of Biological Sciences, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom
10Theodor-Boveri-Institute, Department of Biotechnology and Biophysics, Biocenter, Julius Maximilian University, University of Würzburg, Würzburg, Germany
11Interdisciplinary Center for Clinical Resreach (IZKF) /Departments of Medicine II, Würzburg University Hospital, Würzburg, Germany

In the time window of bone marrow engraftment and immune reconstitution, patients undergoing hematopoietic cell transplantation (HCT) are vulnerable to life-threatening opportunistic infections, such as invasive fungal infections of the lung. Innate immune mechanisms, importantly tissue-resident alveolar macrophages (AMs), have been described as a first line of defense against fungal pathogens Therefore, we addressed how defined cytokines orchestrate AM responses to A. fumigatus in vivo after allogeneic HCT (allo-HCT).

We employed super-resolution and dynamic confocal microscopy to study the impact of cytokines, mainly M-CSF and IL-34, on primary AMs phenotype and migration behavior in vitro. Additionally, we performed functional in vitro assays to study AMs phagocytic behavior. To study the outcome of exogenous cytokine stimulation on the pulmonary immune response in vivo we employed mouse models of allo-HCT (8 Gy TBI, C57Bl/6àBALB/c) and invasive A. fumigatus infection. To this end, we monitored the survival and clinical performance of the mice and investigated local host-pathogen interaction using flow cytometry and 3D light sheet fluorescence microscopy.

HCT recipients survived A. fumigatus infection when infected 6 days but not 4 days after HCT. AMs showed the highest frequency, proliferation and phagocytic activity in the lung, when compared to neutrophils and monocytes, suggesting that tissue-resident AMs were responsible for protecting mice from A. fumigatus infection. This observation was confirmed by selective AM depletion, which rendered mice vulnerable to uncontainable infection. Subsequently, we investigated whether cytokines could boost AMs to achieve earlier protection. In vitro, M-CSF but not IL-34, increased AMs migration speed (0.52 vs. 0.3 µm/min, respectively) and versatility (diffusion co-efficient of 0.78 vs. 0.6 µm2/min, respectively). Next, we treated HCT-recipients with M-CSF and subsequently infected them intratracheally with A. fumigatus 4 days after HCT. M-CSF boosted myelopoiesis by 2-fold and, importantly, locally expanded tissue-resident AMs by 1.5-fold. Additionally, M-CSF improved AM killing capacity and protected 90% of HCT recipients from lethal A. fumigatus infection on day 4 after HCT. Additionally, M-CSF fostered lung tissue integrity and reduced serum levels of pro-inflammatory cytokines. Finally, M-CSF treatment did not protect from lethal aspergillosis upon local depletion of AMs in HCT recipients supporting the importance of a functional pool of tissue-resident AMs to protect from pulmonary infections maintaining lung function.

Conclusively, these data support that M-CSF holds great potential for clinical application by fostering tissue-resident AMs responsiveness to preserve lung function and protect from early A. fumigatus infections in HCT recipients.

Disclosures: Einsele: BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel Grants, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Grants, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants; Sanofi: Consultancy, Honoraria, Research Funding; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Other: travel grants.

*signifies non-member of ASH